Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles

[Image: see text] GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wang, Yingcai, Liu, Jiwen (Jim), Dransfield, Paul J., Zhu, Liusheng, Wang, Zhongyu, Du, Xiaohui, Jiao, Xianyun, Su, Yongli, Li, An-rong, Brown, Sean P., Kasparian, Annie, Vimolratana, Marc, Yu, Ming, Pattaropong, Vatee, Houze, Jonathan B., Swaminath, Gayathri, Tran, Thanhvien, Nguyen, Khanh, Guo, Qi, Zhang, Jane, Zhuang, Run, Li, Frank, Miao, Lynn, Bartberger, Michael D., Correll, Tiffany L., Chow, David, Wong, Simon, Luo, Jian, Lin, Daniel C.-H., Medina, Julio C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2013
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4027505/
https://ncbi.nlm.nih.gov/pubmed/24900707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml300427u
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados